LDLs stimulate p38 MAPKs and wound healing through SR-BI independently of Ras and PI3 kinase

Journal of Lipid Research

Volumn 50, Issue 1, 2009, Pages 81-89

  Bulat, Natasa ^a   Waeber, Gérard ^b   Widmann, Christian ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Fibroblasts; Mitogenactivated protein kinase; Scavenger receptor class B type I

Indexed keywords

LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; SCAVENGER RECEPTOR BI; CD36 ANTIGEN; LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WOUND CLOSURE; WOUND HEALING; ANIMAL; METABOLISM; MOUSE; MOUSE MUTANT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD36; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 63449112726     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800119-JLR200     Document Type: Article

References (49)

1. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. the road ahead. Cell. 104: 503-516.
2. Lee, R. T., and P. Libby. 1997. The unstable atheroma. Arterioscler. Thromb. Vasc. Biol. 17: 1859-1867.
3. Wilensky, R. L., and D. Hamamdzic. 2007. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr. Opin. Cardiol. 22: 545-551.
4. Stocker, R., and J. F. Keaney, Jr. 2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478.
5. Bhakdi, S., K. J. Lackner, S. R. Han, M. Torzewski, and M. Husmann. 2004. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb. Haemost. 91: 639-645.
6. Dobreva, I., G. Waeber, and C. Widmann. 2006. Lipoproteins and mitogen-activated protein kinase signaling: a role in atherogenesis? Curr. Opin. Lipidol. 17: 110-121.
7. Ohashi, N., A. Matsumori, Y. Furukawa, K. Ono, M. Okada, A. Iwasaki, T. Miyamoto, A. Nakano, and S. Sasayama. 2000. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler. Thromb. Vasc. Biol. 20: 2521-2526.
8. Mehta, J. L., N. Sanada, C. P. Hu, J. Chen, A. Dandapat, F. Sugawara, H. Satoh, K. Inoue, Y. Kawase, K. Jishage, et al. 2007. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 100: 1634-1642.
9. Morris, J. B., A. R. Olzinski, R. E. Bernard, K. Aravindhan, R. C. Mirabile, R. Boyce, R. N. Willette, and B. M. Jucker. 2008. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler. Thromb. Vasc. Biol. 28: 265-271.
10. Sartore, S., A. Chiavegato, E. Faggin, R. Franch, M. Puato, S. Ausoni, and P. Pauletto. 2001. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 89: 1111-1121.
11. Xu, F., J. Ji, L. Li, R. Chen, and W. C. Hu. 2007. Adventitial fibroblasts are activated in the early stages of atherosclerosis in the apolipoprotein E knockout mouse. Biochem. Biophys. Res. Commun. 352: 681-688.
12. Dobreva, I., G. Waeber, V. Mooser, R. W. James, and C. Widmann. 2003. LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway. J. Lipid Res. 44: 2382-2390.
13. Dobreva, I., O. Zschörnig, R. W. James, G. Waeber, and C. Widmann. 2005. Cholesterol is the major component of native lipoproteins activating the p38 MAPKs. Biol. Chem. 368: 909-918.
14. Dobreva, I., G. Waeber, R. W. James, and C. Widmann. 2006. IL-8 secretion by fibroblasts induced by low-density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure. J. Biol. Chem. 281: 199-205.
15. Rus, H. G., R. Vlaicu, and F. Niculescu. 1996. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 127: 263-271.
16. Tedgui, A., and Z. Mallat. 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86: 515-581.
17. Yang, J-Y., and C. Widmann. 2001. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol. Cell. Biol. 21: 5346-5358
18. Dull, T., R. Zufferey, M. Kelly, R. J. Mandel, M. Nguyen, D. Trono, and L. Naldini. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
19. Jordan, M., A. Schallhorn, and F. M. Wurm. 1996. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24: 596-601.
20. Havel, R. J., H. A. Eder, and J. H. Bragton. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
21. James, R. W., and D. Pometta. 1990. Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis. 83: 35-45.
22. 317-326 requires p53 and PUMA to sensitize tumor cells to genotoxins. Mol. Cancer Res. 5: 497-507.
23. Brancho, D., N. Tanaka, A. Jaeschke, J. J. Ventura, N. Kelkar, Y. Tanaka, M. Kyuuma, T. Takeshita, R. A. Flavell, and R. J. Davis. 2003. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 17: 1969-1978.
24. Ganiatsas, S., L. Kwee, Y. Fujiwara, A. Perkins, T. Ikeda, M. A. Labow, and L. I. Zon. 1998. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc. Natl. Acad. Sci. USA. 95: 6881-6886.
25. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269: 5241-5248.
26. Stein, R. C., and M. D. Waterfield. 2000. PI3-kinase inhibition: a target for drug development? Mol. Med. Today. 6: 347-357.
27. Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, and P. N. Tsichlis. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 81: 727-736.
28. Grewal, T., I. de Diego., M. F. Kirchhoff, F. Tebar, J. Heeren, F. Rinninger, and C. Enrich. 2003. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J. Biol. Chem. 278: 16478-16481.
29. Krieger, M., and K. Kozarsky. 1999. Influence of the HDL receptor SR-BI on atherosclerosis. Curr. Opin. Lipidol. 10: 491-497.
30. Nieland, T. J., M. Penman, L. Dori, M. Krieger, and T. Kirchhausen. 2002. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc. Natl. Acad. Sci. USA. 99: 15422-15427.
31. Rius, J., J. Martinez-Gonzalez, J. Crespo, and L. Badimon. 2004. Involvement of neuron-derived orphan receptor-1 (NOR-1) in LDL-induced mitogenic stimulus in vascular smooth muscle cells: role of CREB. Arterioscler. Thromb. Vasc. Biol. 24: 697-702.
32. Maier, J. A., L. Barenghi, S. Bradamante, and F. Pagani. 1996. Induction of human endothelial cell growth by mildly oxidized low density lipoprotein. Atherosclerosis. 123: 115-121.
33. Zhu, Y., H. Liao, N. Wang, K. S. Ma, L. K. Verna, J. Y. Shyy, S. Chien, and M. B. Stemerman. 2001. LDL-activated p38 in endothelial cells is mediated by Ras. Arterioscler. Thromb. Vasc. Biol. 21: 1159-1164.
34. Kimura, T., K. Sato, E. Malchinkhuu, H. Tomura, K. Tamama, A. Kuwabara, M. Murakami, and F. Okajima. 2003. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23: 1283-1288.
35. Widmann, C., S. Gibson, M. B. Jarpe, and G. L. Johnson. 1999. MAPK pathways: conservation of a three-kinase module from yeast to man. Physiol. Rev. 79: 143-180.
36. Johnson, G. L., and R. Lapadat. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298: 1911-1912.
37. Ge, B., H. Gram, F. Di Padova, B. Huang, L. New, R. J. Ulevitch, Y. Luo, and J. Han. 2002. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α. Science. 295: 1291-1294.
38. Kang, Y. J., A. Seit-Nebi, R. J. Davis, and J. Han. 2006. Multiple activation mechanisms of p38alpha mitogen-activated protein kinase. J. Biol. Chem. 281: 26225-26234.
39. 2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc. Natl. Acad. Sci. USA. 94: 3004-3009.
40. Li, Y., R. F. Schwabe, T. Devries-Seimon, P. M. Yao, M. C. Gerbod-Giannone, A. R. Tall, R. J. Davis, R. Flavell, D. A. Brenner, and I. Tabas. 2005. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-a and interleukin-6: model of NF-κ B- and MAP kinase-dependent inflammation in advanced atherosclerosis. J. Biol. Chem. 280: 21763-21772.
41. Rodriguez-Viciana, P., P. H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, M. J. Fry, M. D. Waterfield, and J. Downward. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 370: 527-532.
42. Sachinidis, A., S. Seewald, P. Epping, C. Seul, Y. Ko, and H. Vetter. 1997. The growth-promoting effect of low-density lipoprotein may be mediated by a pertussis toxin-sensitive mitogen-activated protein kinase pathway. Mol. Pharmacol. 52: 389-397.
43. Acton, S. L., P. E. Scherer, H. F. Lodish, and M. Krieger. 1994. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269: 21003-21009.
44. Stangl, H., M. Hyatt, and H. H. Hobbs. 1999. Transport of lipids from high and low density lipoproteins via scavenger receptor-BI. J. Biol. Chem. 274: 32692-32698.
45. Trigatti, B., H. Rayburn, M. Vinals, A. Braun, H. Miettinen, M. Penman, M. Hertz, M. Schrenzel, L. Amigo, A. Rigotti, et al. 1999. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl. Acad. Sci. USA. 96: 9322-9327.
46. Kozarsky, K. F., M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader. 2000. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20: 721-727.
47. Ueda, Y., E. Gong, L. Royer, P. N. Cooper, O. L. Francone, and E. M. Rubin. 2000. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J. Biol. Chem. 275: 20368-20373.
48. Hirano, K., S. Yamashita, Y. Nakagawa, T. Ohya, F. Matsuura, K. Tsukamoto, Y. Okamoto, A. Matsuyama, K. Matsumoto, J. Miyagawa, et al. 1999. Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ. Res. 85: 108-116.
49. Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart, et al. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 101: 2411-2417.